News | October 11, 2023
AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
The state-of-the-art digital PETCT imaging system, highlights a significant advancement in the fight against cancer and detects other lesions offering patient centric services
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Subscribe To Our Newsletter & Stay Updated
